<code id='991FF00210'></code><style id='991FF00210'></style>
    • <acronym id='991FF00210'></acronym>
      <center id='991FF00210'><center id='991FF00210'><tfoot id='991FF00210'></tfoot></center><abbr id='991FF00210'><dir id='991FF00210'><tfoot id='991FF00210'></tfoot><noframes id='991FF00210'>

    • <optgroup id='991FF00210'><strike id='991FF00210'><sup id='991FF00210'></sup></strike><code id='991FF00210'></code></optgroup>
        1. <b id='991FF00210'><label id='991FF00210'><select id='991FF00210'><dt id='991FF00210'><span id='991FF00210'></span></dt></select></label></b><u id='991FF00210'></u>
          <i id='991FF00210'><strike id='991FF00210'><tt id='991FF00210'><pre id='991FF00210'></pre></tt></strike></i>

          
          WSS
          Alastair Grant/AP

          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

          advertisement

          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge